

Pfizer Limited

The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

February 5, 2021

The Corporate Relationship Dept. BSE Limited 1st Floor, P.J.Towers Dalal Street, Fort Mumbai - 400 001 Scrip Code: 500680 The Manager, Listing Dept. The National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Re-appointment of Mr. S. Sridhar as the Managing Director.

Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company has at their Meeting held today re-appointed Mr. S. Sridhar (DIN: 05162648) as the Managing Director of the Company for a further period of 5 years with effect from March 18, 2021. The re-appointment of Mr. S. Sridhar will be subject to the approval of shareholders at the ensuing Annual General Meeting of the Company.

Mr. S. Sridhar is leading Pfizer Inc's commercial business in India. Mr. Sridhar has in his career successfully steered many strategic projects, global brand launches, business restructuring actions, Mergers & Acquisitions and Joint Ventures. A Chartered Accountant with three decades of experience, Mr. Sridhar has successfully donned multiple hats in his career as Chief Financial Officer, Business Unit and Supply Chain Head and the Managing Director of Pfizer Limited business since March 2016. Mr. Sridhar was appointed as the Executive Director of the Company in May 2013.

Mr. Sridhar has successfully led the implementation of merger of Wyeth Limited with Pfizer Limited that has resulted in the two listed entities successfully combining talent and product portfolios to create a single 'go to market' strategy, stronger market presence and increased long term shareholder value. Mr. Sridhar was also responsible for developing the integrated company's institutional business strategy which resulted in a strong Pfizer product portfolio presence in major institutions across the country and leading the development of company's multi-channel marketing strategy.

Mr. Sridhar is an Executive Member of Organisation of Pharmaceutical Producers of India (an association of Research Based Organisations) and is also the Chair of its Finance and Taxation Work Group. Mr. Sridhar is also the former Chair of The Federation of Indian Chambers of Commerce and Industry (FICCI) Pharma Committee. In this capacity, Mr. Sridhar has effectively advocated for policies that are pro patient, encourage innovation and provide for a positive environment for the industry to grow. Prior to joining Pfizer, Mr. Sridhar spent 13 years with Diageo, the world's largest alcoholic beverages company. Mr. Sridhar was the Finance Director when he left Diageo India.

Mr. Sridhar does not hold any shares in the Company and none of the Directors are related to him. Mr. Sridhar is not debarred or disqualified from holding the office of Director by virtue of any order from MCA/SEBI or any such statutory authority.

We request you to kindly take the above on record.

Thanking you,

Yours truly, For Pfizer Limited

er

Prajeet Nair Company Secretary